Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Tim K who wrote (2836)	1/6/1999 4:55:00 PM
From: EZLibra	Read Replies (1) \| Respond to of 3702

Hi Tim, thanks. The new patent is global and covers all receptors in a tumor blood vessel, thus also covering delivery made by any and all other agents. Carbomed and Oxygene (both licensed to Zeneca) come to mind but most of the 150 or so companies and labs which have invested so far in antiangiogenesis haven't been as 'forthcoming' as an Entremed. It might be easier for us to separate from the pack and call this Vascular or Vessel Targeting technology even though it is antiangiogenesis. The concept is a few light years ahead of the ENMD type aa and, besides, since we own it I guess we can call it what we want. Other pharma, biotechs in the aa field have to pay attention to TCLN now, and I think when the licensee is revealed they will all fall in line and start the royalty stream. I've been researching this since TCLN bought Peregrine in '97, Tim, and first heard of Peregrine through BioCentury in '96. Other comments are welcome.